Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AQST Aquestive Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AQST
Price (delayed)
$2.79
Market cap
$275.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$326.16M
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan,
Highlights
Aquestive Therapeutics's gross margin has increased by 17% YoY
Aquestive Therapeutics's quick ratio has surged by 136% YoY but it has decreased by 28% QoQ
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
AQST's net income is down by 25% since the previous quarter
The EPS has declined by 11% since the previous quarter
Key stats
What are the main financial stats of AQST
Market
Valuations
Earnings
Shares outstanding
98.87M
Market cap
$275.85M
Enterprise value
$326.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
Revenue
$57.56M
Gross profit
$39.69M
Operating income
-$30.77M
Net income
-$44.14M
EBIT
-$27.33M
EBITDA
-$26.62M
Free cash flow
-$35.92M
Per share
Balance sheet
Liquidity
EPS
-$0.51
EPS diluted
-$0.51
Free cash flow per share
-$0.41
Book value per share
-$0.66
Revenue per share
$0.66
TBVPS
$1.17
Total assets
$101.42M
Total liabilities
$161.58M
Debt
$121.85M
Equity
-$60.16M
Working capital
$69.36M
Debt to equity
-2.03
Current ratio
4.68
Quick ratio
4.18
Net debt/EBITDA
-1.89
Margins
Efficiency
Dividend
EBITDA margin
-46.2%
Gross margin
69%
Net margin
-76.7%
Operating margin
-53.5%
Return on assets
-38.5%
Return on equity
N/A
Return on invested capital
-20.6%
Return on capital employed
-33.1%
Return on sales
-47.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AQST stock price
How has the Aquestive Therapeutics stock price performed over time
Intraday
1.09%
1 week
-7%
1 month
8.14%
1 year
-15.2%
YTD
-21.63%
QTD
-3.79%
Financial performance
How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$57.56M
Gross profit
$39.69M
Operating income
-$30.77M
Net income
-$44.14M
Gross margin
69%
Net margin
-76.7%
The operating income has plunged by 104% YoY and by 46% from the previous quarter
Aquestive Therapeutics's operating margin has shrunk by 79% YoY and by 49% QoQ
The company's gross profit rose by 33% YoY but it fell by 2.9% QoQ
The net margin has contracted by 28% from the previous quarter
Price vs fundamentals
How does AQST's price correlate with its fundamentals
Growth
What is Aquestive Therapeutics's growth rate over time
Valuation
What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
The EPS has declined by 11% since the previous quarter
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
AQST's P/S is 35% above its 5-year quarterly average of 3.1 but 28% below its last 4 quarters average of 5.8
Aquestive Therapeutics's revenue has increased by 14% YoY but it has decreased by 2.3% from the previous quarter
Efficiency
How efficient is Aquestive Therapeutics business performance
AQST's ROA has dropped by 187% year-on-year and by 13% since the previous quarter
The return on sales has declined by 45% since the previous quarter
The company's return on invested capital fell by 40% QoQ
Dividends
What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AQST.
Financial health
How did Aquestive Therapeutics financials performed over time
The company's total assets is 37% lower than its total liabilities
Aquestive Therapeutics's quick ratio has surged by 136% YoY but it has decreased by 28% QoQ
The current ratio has surged by 109% year-on-year but it has declined by 27% since the previous quarter
AQST's debt to equity has dropped by 92% year-on-year but it is up by 23% since the previous quarter
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.